A tetrahydroisoquinoline compound as a potassium channel modulator and preparation and application thereof. Specifically, the compound has the structure as shown in formula A.

##STR00001##

A tetrahydroisoquinoline compound as a potassium channel modulator and preparation and application thereof. Specifically, the compound has the structure as shown in formula A.

##STR00001##

The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity. ##STR00001##

The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity. ##STR00001##

Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable salt thereof, which can be used as a histone deacetylase inhibitor, has a selective inhibitory effect on HDAC6, and has characteristics such as a high efficiency, low toxicity and ideal pharmacokinetic properties.

##STR00001##

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

##STR00001##

The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.

The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.